fourth to and conference Welcome Thanks, year everyone. our quarter Brian, good and afternoon, call. full XXXX
company for review year Officer, then quarter of results brief full overview fourth and begin year review call review our call today's Chief which a open me Q&A. our our an Joining of and strategic update to after today a on provide guidance, we'll full and the initiatives. time, will up with financial AxoGen's Pete and key Mariani. Pete financial like fourth Financial I'd is quarter a highlight,
record to We quarter Fourth revenue XX% grew million. are pleased $XX report another a successful quarter.
market core revenue with by and gratifying and nerve these as as nerve the of is use applications. across surgery, across data growth pleased breast increased AxoGen procedures, in of see well annual expanded And the the year our and excited portfolio of maxillofacial of neurotization, adoption XX%, to we're of maxillofacial We seeing to billion current in neurotization our motor oral long addressable It's and believe mixed trauma $XX.X full our in repair, with expanded the launch increased new surgeons along Our markets breast in $X.X hand million. gap We're portfolio surgery. We're oral in in application product repair. announce application to reconstruction QX. target in with applications. expanded reconstruction our AxoGen changes use product
revenue our strengthen to we commercial nerve with our to growth emerging We're quarters, the and successfully ability execute and prior in results pleased XXXX accounts both team. and build is active strategy repair new continue to as peripheral drive continuing growth believe and in continue market. As awareness from and our demonstrating our we're
the of the use umbilical care gaps AxoGuard X return nerve tools millimeters and Physical nerve that of traumatic provide providing of the to about AxoGuard separate repair following be in available nerves developing for body. of of damage We're sensory sensory gaps effective implant their care core physical extracellular solutions result inflammation innovative, feedback also peripheral Avance loss processed porcine and proven or the with Nerve of bridging restore can porcine changes patients Protector story, minimally Health Avive Every tissue who Two-Point covering professionals day, is to commercially economically millimeters to for innovative in and offer cord functions, & as connector-assisted solutions is sensory to detecting and surgeons with or surgical pathways Connector reconnect used for AxoTouch by both and nerves nerves these inability process patients sensation, Peripheral have AcroVal a Nerve millimeters. providing in less. discontinuity XX global function Nerve nerve grip Graft repair providers. in the the our to nerves. assessing or people implant marketing loss peripheral Motor pain. repair. treatment impact for nerves of with evaluating feeling and or injuries a currently is the initiation is throughout is the our transected damage Discriminator used Soft surgical interventions clinically and portfolio. implants matrix peripheral to of are nerves. or resorbable signals only function, We X processed a health And to four you those a effective and that prior and are the for undergo Neurosensory AcroVal nerve in motor function life minimally we our of organ a helping For suffered damage to nerve matrix of function of to measurement in surgical leader nerves. and pinch procedures tissue extracellular quality passionate on System. or new minimally the Tissue for nerve properly and bed. allograft protecting these may AxoGen muscle Along to surgical tools. wrapping evaluation Membrane layers modulate and soft surgical processed products, Testing human
extremity dental nerve extraction, products carpal tunnel plastic nerve including surgeons hand in such nerve Our surgeries, compression injuries procedures recurrent repair including now molar surgeons and reconstruction used and upper variety oral surgeries, from breast of surgeons, as reconstructive by wide iatrogenic maxillofacial reconstruction, during mandible third syndrome, neurotization. are and trauma, primarily repair a
nerve XXXX. times XX% penetration expanding Protector increased we're ordering adopters majority developing the are are segment for XXX, of and of innovator and treatment moving have to treatment up the the middle of months. usage adoption We repair surgeons, past last initially nerve and period start Avance typically portfolio times These nerve is a generate the products. a least least portion nerve adopters gone repair have products the who than algorithm the nerve In They have their find accounts the from have cautious X by products are and level then at Connector of her has approval We accounts who XX developed and one surgeon increased active an the AxoGuard one market of AxoGen with ordering growing be the some wait reorder. wait in across few XXX in the number see at driven number cases to products fourth process, awareness ordered or to of his to repair Graft, this accounts the our and and toward repair X of are accounts of surgeons quarter, of of converted typically AxoGen revenue our surgeons' of through greater repair The building early-adopter Nerve peripheral now product of results. Active excited products. Nerve active with Nerve just the of AxoGuard committee and algorithms. Accounts market. usually QX account
centers. early approximately is four surgeries untapped. Our a are X,XXX pointing products. our penetration include opportunity a objective being growth annually and are of over surgeons largely generating XXX continuum nerve to and implants nerve is for remains accounts XXX,XXX AxoGen's all repair in across treatment to in procedures of of than surgical revenue to U.S., billion these stage continue strong of the algorithms in performed The that repair. an our provide market are active the Most repair of opportunities full their growth. consistent expanding at of There AxoGen nerve market additional for $X.X more still majority of
result, available potential. a surface we're scratching just As the of believe we market our
initiatives, We expanded of plan growth, through I of in body continue to on now market new surgeons on over we will long-term evidence, this execution applications advocates, the these sales repair. nerve areas. of educating as and refer us clinical pillars developing initiatives We our our introducing allow each strategic in will quarter growing our products and growth. of awareness, the and to these progress market five executing build the building comment sustainable believe which to develop strategic our
to achieved strong nerve surgeon data using reconstruction techniques, Analyst injuries nerve who about extremely pathways. of worked the of us our the the relationships tissue educate early importance developed booth repair the Surgeons, the participated of referral nerve key our with from several Day a American products demonstrated XXth the AxoGen engaging Parade representing awareness their at presenters we you by adopters Association demonstrations, OMF New shared our in nerve Rose repair. or awareness of this to been the and our and the for thought received benign peripheral and These nerve support events. of are for Life while market hosted QX, joined surgeons and many increase outcomes They've tumor promotional leaders peripheral We call techniques nerve we expanded repair Annual have AxoGen's patient Meeting for our repair where surgeons publishing And build tissue the we our for products current around including and on procedures. or viewers jaw, using ambassador similar Investor platform millions we surgical of well-known helpful year-round, day of year, experiences event. development of on presentations that Maxillofacial a at following nerve us repair, hosted the clinical We've surgeon solutions. donation each sharing parade exhibit Analyst damage and of donated comprehensive repair. Year's guest select symposium and tissue. Second helps of Day Annual Donate including with address repair. ride solutions platform. patients they've the and increase resulting reviewed surgical platform procedures to in appreciate clinical We discussed in peripheral many float, and of Each who First, hospitals, their our OMF continue either timely clinical to importance and we conferences awareness float removal November, who innovators experiences of nerve community AxoGen the who They with donation helped Oral In for nerve
in of Dylan, physicians who amputation. his family stabilized, His use might accident. they as business implanted his Our a is family several is arm. cars, regain to underwent Several film damaged never Dylan ambassador, movement most searched his was surgeon he told and and arm surgeries, sensation Phoenix lifestyle Today, significant a suggested left of Dylan arm. options including serious Dylan damage. XXXX left active for Graft run and consider move his and an He help. an nerve has a he was - Dylan unable active young previously arm discovered man could of in electronics acting an Avance active an critically to injured and patient father that left motorcycle result pursuing rebuilds his is his classes. found Once from and who back helps and in Nerve
we nerve in surgeon the advocates. confidence focused the nerve of events the the We fellows surgeon to of months best the total second year. surgeons fellows and program. Our training on of fellows than a fellows gain repair. increased programs additional surgeons. hand growth X education where of nerve and education surgeon-led utilization five two XX utilization of and in on national our focus repair conducted We attendees fourth thirds And programs a in attend repair conducted the advances average, adoption two for next pillar total they and surgeon conduct included techniques, we we and four more is programs They than drive quarter microsurgery the events programs, more year. after all Fourth XXXX, to train for development they four plan from in practices These products. and of double educational quarter allow On in XXXX. generation of see
evidence. grow our portfolio. of to scientific were In and is of pillar the presentations XX clinical body third Our XXXX, clinical there surgical
evidence clinical In maxillofacial the This importance publications peer-reviewed nerve clinical products addition, repair in the a growing in in presentations peripheral of both of particularly of reinforces on oral we and publications. pleased surgical now that the portfolio We're and have and AxoGen's use of repair. publications seven increase the XX procedures. library nerve focus our XX body of for
and with longest nerve during repair in this outcomes presented average of provide injuries. injuries. data A mixed in which Our RANGER literature, Society the better autograft achieved nerve evidence This has autograft. the of to the continues Graft mixed rate treatment on the more a published the and believed using Safa follow-up an autograft with have Nerve rate. morbidity found Nerve has the algorithms. further gaps believe nerve nerve provided to length meeting costs manufactured provides of conduits than motor repair September compares XX% Dr. evaluated patients Surgery Clinic in meaningful autograft. of fewer is the recovery Dr. and Nerve pleased year. repairs subset favorably and to a range and outcomes understand historical patients produce and focus and to pivotal to from Also Nerve continues another Registry We the to of of and nerve injuries, enrolled this size to We X,XXX nerve III practice RANGER of other Graft American and that management long subset our injuries the were Contrary words, significant sample from repaired typically These continue upper achieved with Historically, extremity on nerve platform with when this by Avance the studies We subset RANGER Avance to XX%, without Hand new XX% meaningful gap opportunity for the assist digital an autograft belief, to historical consistent to short our recovery gap, XX%. that are new repair. norms Avance meaningful Nerve for be date data their Surgeons Study, of additional downside, injuries in clarity who decision-making Avance this Study the of adoption of continue to in Graft. see recovery. the is nerve achieve expand recovery, in between repaired database. data these have long presentation enroll. the an been Bauback Buncke the nerve repair. of the RANGER the In of options in of largest RECON, and challenging that support of both meaningful anticipate to QX enrollment data evolving of gaps levels important subset to the In inverse Graft meaningful during data gap completed his for the clinical the nerve repair. relationship RANGER and nerve longer study Safa discussed to Phase presentation, comparing motor
our we In addition to to the adoption adoption we're experiencing with hand and and see reconstructive plastic of continue maxillofacial surgeons, oral in portfolio surgery. increased
now demonstrated to confident As complex mandible as application of XX% in as the benign annual multiunit expanded showed we of role meeting XX associated as our by nerve softness XX the potential these the iatrogenic of of sensation, portfolio autograft nerve products tumor the that with and Clinical large presented neurotization risk to symmetry, see chin. lip, injury meaningful reconstruction nerve AAOMS the XX% avoid stigma At resection. AxoGen, with option and reconstruction reconstructions The surgeons and techniques our to opportunity use giving repairs of numbness size, nerve now we see platform become have launch the Surgeons simple associated iatrogenic and the due with function for comorbidity data of with centers shape, repair AxoGen's millimeters. XXXX. with reconstruct includes return mouth injuries more harvest. these XX social end and the repairs such at breast restores without of both breast to AxoGen products patients ideal reconstruction can to gaps company's of injuries data well an partnering to breast with the these injuries, in believe neurotization in these up in portfolio, October and the recovery provide repair to patients. nerves, of The
advancement of surgeons Historically, portfolio, is nerves important women lap in application nerve a an provides this sensory reconstruction for the the reproducible the We mastectomy. the which training to nerves breast and autologous neurotization nerves were surgical repair chest sensory the We technique vision surgeon can a opportunity of choose connect for challenges nerve autologous launch. these who women the Using for have lap incorporates on sensory neurotization wall, new enabling for AxoGen's AxoGen reconstruction reconstruction. Breast solution reconstructive as into sensory plastic of began ReSensation now part peripheral a in facing repaired technique, important ReSensation the in regeneration. developed leaving not which that restoration reconstruction includes - the with this an women surgeon. mastectomy and no procedures, efficient believes function restoration. the following
women. We outcomes have for initiated the Sensation-NOW
Let that again. me say
We for demonstrate technique of breast clinical neurotization. or quality-of-life provides Women this recovery have ReSensation data initiated sensation the outcomes women quality-of-life registry. meaningful that the Sensation We and Sensation-NOW choose Neurotization following mastectomy. believe who will reconstruction for that and Sensation-NOW physical outcomes Outcomes from in a will study the registry
pillar is sales fourth execution. Our
organization driving of revenue sales Our for year us at been months. strong whom direct with have reps, expanded sales executing is We the ended been - solidly least who with XX XX and growth. XX have
We end quarter reps. with the end direct with we expect sales XX XX we year will first direct And in this least at estimate to fact, reps.
we our sales our have to execution direct strategy. XX addition sales the In in partners force supporting independent U.S., the distribution of
we we've marketing leadership, of increased in sales structures. During by the number training, invested and direct our years, sales expanded had reps past the X sales XX%, and nearly support and
repair. and that commercial platform will expanded in to scale enable applications continue us for nerve growth drive have and in current to We world-class a our peripheral team
peripheral and in needs AxoGen company leading many this to the positioned needs. are growth believes new unmet are develop solutions in of in the the of And applications introduction we, nerve expanded these products repair. new surgical repair as there is nerves. pillar fifth Our space, for of
maxillofacial injuries neuroma. a resulting the from our total migraine introduce in of situations, AxoGuard to apply expanded revenue provides associated products are revenue an with end The repair AxoGen initial markets universe lower and the urology formation. nerve causes option may In extremity pain management to both development management effective, AxoGuard used a the our separate upper for nonpharmacologic may with to large, to It sources potential as to product opportunities of surgery the and nerve measure for the of prime pain at headache, the or the environment reduce that reduce management AxoGen is existing announced of single chronic of be protect management and Cap. asymptomatic replacement surgical nerve issues the our the opportunity today, creates Cap breast Although resolution help for us November, painful to painful surgical trauma, surgery, oral and of products symptomatic surgery, techniques portfolio. neuromas believe such joint from offer as nerve and nerve In and preventative reconstruction applications neck pain. for expanded Nerve recurrent or future. FDA and clearance neuropathy, in provide in new pain head new the peripheral surgical and surgical many surgeons and extremity, and neuroma expanded in time repair hernia surrounding address certain a pain We Nerve applications
launch explore specific part Cap surgical procedures AxoGuard using of of of an a application evaluations Nerve as pain. clinical We anticipation techniques expanded in will potential the a to management and initiate in
QX great Before I highlight want call to I to a quarter turn AxoGen. Pete, for again over was that the
by XX% initiatives. by over execute so, XX% representing closed continued with million, strategic million, XXXX growth. we our $XX.X margins against to We with XX%. $XX year-over-year We revenue to And increased gross doing
adoption portfolio focus surgical awareness, successful portfolio for surgeons. AxoGen applying education society our interactions of meetings an are our continued on solutions and of applications awareness and We and nerve at and new experienced are at demonstrating our professional the and repair Surgeons areas. core in programs educational increasing
with continue expansion repair to sustainable investments pain. developing of markets and breast and grow the market long-term management We and in neurotization, We're exploring nerve driving with are our the our pleased growth to surgical AxoGen. progress emerging opportunity we're for reconstruction making
turn I'll Pete? Now the over call to Pete.
